Acquisition of the multi-source injectables business from Baxter gives US-based West-Ward, a subsidiary of Hikma, a platform to win contract manufacturing business. By expanding in the sector West-Ward also wants to tackle drug shortages that have become an increasing problem.
“Many of these shortages are due to an increase in the number of contract pharmaceutical manufacturers that are reducing or eliminating production. We see this as a major opportunity for West-Ward and for Hikma”, Michael Raya, president and CEO of West-Ward, said.